US › Healthcare

Inhibikase Therapeutics Inc (IKT)

US · Healthcare · Biotechnology

$2.30-0.43%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-19.6M

EPS

$-0.11

EPS estimate

$-0.09

EPS came in at -0.11 against a street estimate of -0.09 — a miss of 22.2%.

Key statistics

Market cap

$333.5M

Forward P/E

0.0

P/B

2.13

Book value

$0.88

EPS (TTM)

$-0.44

52-week high

$2.61

52-week low

$1.33

50-day MA

$2.31

200-day MA

$1.90

Beta

0.96

Analyst view

Analysts rate Inhibikase Therapeutics Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.00.

Shareholding

Insiders

6.09%

Institutions

92.23%

Largest institutional holders

Fund	Stake
Sands Capital Ventures, LLC	9.33%
Soleus Capital Management, L.P.	7.79%
Trails Edge Capital Partners, LP	6.49%
Fairmount Funds Management LLC	6.18%
ADAR1 Capital Management LLC	4.73%
Kalehua Capital Management LLC	4.65%
BlackRock Inc	4.52%
Blackstone Inc	4.26%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Inhibikase Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.